Normalize and accept the desire to procrastinate without feeling the need to act on it. Just because you don’t want to work ...

Much has changed in how we understand and treat eating disorders. Some significant aspects have remained consistent or ...

People who master the art of being unbothered let small annoyances roll off their backs and focus on nurturing a life that ...

Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. ("Zydus Group"), today announced that the U.S. Food and Drug Administration (FDA ...

A randomized trial showed that a smartphone-delivered digital CBT intervention improved generalized anxiety disorder symptoms in adults. The self-paced program uses evidence-based CBT techniques such ...

Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences (Zydus Group), today announced that the U.S. Food and Drug Administration (FDA) has ...

Final 2025 global cohort onboarding, with applications now open for 2026WILMINGTON, Mass.--(BUSINESS WIRE)--$CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the ...

The Shreiber Family Pet Therapy Program of Rowan University stands ready to guide, train and evaluate pilot programs under ...

If approved, CUTX-101 will be the first and only FDA-approved treatment available for Menkes disease, a rare X-linked ...

The FDA has “proactively” granted Johnson & Johnson a coveted speedy review under the Commissioner’s National Priority ...

The drug, CUTX-101, is intended for the treatment of Menkes disease, a rare X-linked recessive genetic disorder affecting ...